Intra-Cellular Current Valuation

ITCI
 Stock
  

USD 53.57  3.45  6.05%   

Intra-Cellular Ther fundamentals help investors to digest information that contributes to Intra-Cellular Ther's financial success or failures. It also enables traders to predict the movement of Intra-Cellular Stock. The fundamental analysis module provides a way to measure Intra-Cellular Ther's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Intra-Cellular Ther stock.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Intra-Cellular Current Valuation Analysis

Intra-Cellular Ther's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
 2021 2022 (projected)
Interest Expense33.1 K33.97 K
Gross Profit75.77 M81.75 M
Enterprise Value 
 = 
Market Cap + Debt 
-  
Cash 
More About Current Valuation | All Equity Analysis

Current Intra-Cellular Ther Current Valuation

    
  4.36 B  
Most of Intra-Cellular Ther's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Intra-Cellular Ther is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Intra-Cellular Current Valuation Driver Correlations

Understanding the fundamental principles of building solid financial models for Intra-Cellular Ther is extremely important. It helps to project a fair market value of Ford stock properly, considering its historical fundamentals such as Current Valuation. Since Intra-Cellular Ther's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Intra-Cellular Ther's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Intra-Cellular Ther's interrelated accounts and indicators.

Intra-Cellular Current Valuation Historical Pattern

Today, most investors in Intra-Cellular Ther Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Intra-Cellular Ther's growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current valuation growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Intra-Cellular Ther current valuation as a starting point in their analysis.
   Intra-Cellular Ther Current Valuation   
Share
       Timeline  
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Compare to competition

In accordance with the recently published financial statements, Intra-Cellular Ther has a Current Valuation of 4.36 B. This is 69.64% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The current valuation for all United States stocks is 73.77% higher than that of the company.

Intra-Cellular Current Valuation Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Intra-Cellular Ther's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Intra-Cellular Ther could also be used in its relative valuation, which is a method of valuing Intra-Cellular Ther by comparing valuation metrics of similar companies.
Intra-Cellular Ther is currently under evaluation in current valuation category among related companies.

Intra-Cellular Ther Current Valuation Drivers

We derive many important indicators used in calculating different scores of Intra-Cellular Ther from analyzing Intra-Cellular Ther's financial statements. These drivers represent accounts that assess Intra-Cellular Ther's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Intra-Cellular Ther's important valuation drivers and their relationship over time.
201720182019202020212022 (projected)
Net Income Per Employee(2 M)(2.13 M)(447.64 K)(591.09 K)(554.93 K)(598.74 K)
Revenue Per Employee7.85 K5.02 K18459.4 K163.68 K176.6 K
Average Assets381.88 M400.13 M296.14 M602.7 M586.77 M498.29 M
Earnings Before Interest Taxes and Depreciation Amortization EBITDA(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings Before Interest Taxes and Depreciation Amortization USD(98.62 M)(154.76 M)(147.24 M)(226.46 M)(283.59 M)(291.05 M)
Earnings before Tax(98.83 M)(155.13 M)(147.72 M)(226.99 M)(284.12 M)(291.6 M)
Average Equity366.64 M371.23 M241.82 M544.06 M517.6 M443.81 M
Enterprise Value737.94 M553.56 M1.82 B2.28 B4.18 B4.51 B
Free Cash Flow(81.22 M)(118.56 M)(128.68 M)(230.34 M)(259.87 M)(266.71 M)
Invested Capital419.49 M265.96 M130.47 M648.16 M368.21 M332.89 M
Invested Capital Average333.71 M306.89 M193.88 M423.85 M451.48 M372.11 M
Market Capitalization790.28 M623.33 M1.9 B2.55 B4.26 B4.6 B
Tangible Asset Value471.49 M357.21 M251.19 M717.31 M489.92 M435.39 M
Working Capital455.01 M319.14 M194.1 M654.05 M413.92 M379.9 M

Intra-Cellular Fundamentals

About Intra-Cellular Ther Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Intra-Cellular Ther's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Intra-Cellular Ther using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Intra-Cellular Ther based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, develops novel drugs for the treatment of neuropsychiatric and neurologic diseases by targeting intracellular signaling mechanisms within the central nervous system in the United States. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York. Intra-Cellular Ther operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 512 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Intra-Cellular Ther without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Intra-Cellular Ther using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Intra-Cellular Ther Piotroski F Score and Intra-Cellular Ther Altman Z Score analysis. Note that the Intra-Cellular Ther information on this page should be used as a complementary analysis to other Intra-Cellular Ther's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Intra-Cellular Stock analysis

When running Intra-Cellular Ther price analysis, check to measure Intra-Cellular Ther's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Intra-Cellular Ther is operating at the current time. Most of Intra-Cellular Ther's value examination focuses on studying past and present price action to predict the probability of Intra-Cellular Ther's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Intra-Cellular Ther's price. Additionally, you may evaluate how the addition of Intra-Cellular Ther to your portfolios can decrease your overall portfolio volatility.
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Global Correlations
Find global opportunities by holding instruments from different markets
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Go
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Is Intra-Cellular Ther's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intra-Cellular Ther. If investors know Intra-Cellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intra-Cellular Ther listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
5.1 B
Quarterly Revenue Growth YOY
1.77
Return On Assets
-0.28
Return On Equity
-0.5
The market value of Intra-Cellular Ther is measured differently than its book value, which is the value of Intra-Cellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intra-Cellular Ther's value that differs from its market value or its book value, called intrinsic value, which is Intra-Cellular Ther's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intra-Cellular Ther's market value can be influenced by many factors that don't directly affect Intra-Cellular Ther's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intra-Cellular Ther's value and its price as these two are different measures arrived at by different means. Investors typically determine Intra-Cellular Ther value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intra-Cellular Ther's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.